| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11014965 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10435438 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10208089 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10106579 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10562934 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752190 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US10835574 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US11535650 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
Zilbrysq is owned by Ucb Inc.
Zilbrysq contains Zilucoplan Sodium.
Zilbrysq has a total of 8 drug patents out of which 0 drug patents have expired.
Zilbrysq was authorised for market use on 17 October, 2023.
Zilbrysq is available in solution;subcutaneous dosage forms.
Zilbrysq can be used as treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan.
Drug patent challenges can be filed against Zilbrysq from 18 October, 2027.
The generics of Zilbrysq are possible to be released after 12 June, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
Drugs and Companies using ZILUCOPLAN SODIUM ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
Dosage: SOLUTION;SUBCUTANEOUS
ZILBRYSQ family patents
